Conjustar

Focus: Conjustar is a China-based biotechnology company specializing in novel miniaturized coupled drugs, peptide/nanoantibody-coupled drugs focused on oncology. The company operates as a pre-revenue biotech with an early-stage pipeline in solid tumors.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Conjustar

AI assessmentNot Hiring

No open roles listed right now. Follow Conjustar to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SC-102

Advanced Solid Cancers

Phase 1

Clinical Trials (1)

NCT06710158Study of SC-102 in Patients With Advanced Solid Tumors

Phase 1

Help build intelligence for Conjustar

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on differentiated modality (peptide/nanoantibody-coupled drugs) with limited competitive saturation in the market
Early-stage company offers potential for significant career acceleration and direct impact on drug development strategy
China-based biotech provides exposure to growing Asian biotech ecosystem and emerging market advantages

Watch Out For

No active job openings currently posted, indicating minimal near-term hiring or potential organizational constraints
Very early pipeline (2 Phase 1 programs, 1 Phase 2) with no marketed products or revenue, creating inherent execution and funding risk
Sparse public information on funding, employee count, financials, and company milestones limits visibility into stability and trajectory

Generated by Claude from Conjustar's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SC-101

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT06220838Study SC-101 in Subjects With Advanced Malignancies

Phase 1

SC-101

TNBC - Triple-Negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT07080619SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline